Car T-Cell Therapy

Janssen and Legend Biotech have begun a rolling submission of a biologics license application to the FDA for ciltacabtagene autoleucel to treat adults with relapsed or refractory multiple myeloma.

Molecular and cellular characteristics of commercial chimeric antigen receptor T-cell therapies appeared associated with treatment response and toxicity among patients with large B-cell lymphoma, according to a study in Nature Medicine.

Last week, the FDA approved margetuximab-cmkb for the treatment of patients with metastatic HER2-positive breast cancer. It was the top story in hematology/oncology.

Since 2014, when we took the helm of HemOnc Today as joint Chief Medical Editors, the overall progress in oncology has been spectacular.

This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.

An investigational chimeric antigen receptor T-cell therapy showed antitumor activity among patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to data presented at the virtual ASH Annual Meeting and Exposition.

Ryan Cassaday, MD, associate professor at University of Washington & Fred Hutchinson Cancer Research Center and attending physician at Seattle Cancer Care Alliance, discussed emerging strategies and developments in HIV malignancies, CD-22 targeted CAR T-cells and other presentations at the ASH Annual Meeting and Exposition.

First-line therapy with axicabtagene ciloleucel induced an objective response in 85% of patients with high-risk large B-cell lymphoma, according to phase 2 study results presented at the virtual ASH Annual Meeting and Exposition.

Young patients with B-cell acute lymphoblastic leukemia had shorter RFS and EFS if they received blinatumomab before chimeric antigen receptor T-cell therapy, according to results presented at the virtual ASH Annual Meeting and Exposition.

Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition